Skip to main content
Medicines, medical devices

Guidance and regulation

Skip to results
447 results sorted by Most viewed
  • E-learning modules for healthcare professionals on minimising the risks of using medicines and information on how to access medical device modules.

  • Guidance on the submission, processing and assessment of all completed paediatric studies sponsored by marketing authorisation holders (MAHs).

  • How to apply for an exceptional use authorisation to place medical devices on the UK market.

  • Information for patients, healthcare professionals and developers of new medicines

  • Also covering requests for waivers or deferrals and concerning the operation of the compliance check.

  • A step-by-step guide on using the MORE Platform for Submissions of device related incidents.

  • How to comply with the regulatory requirements for manufacturing custom-made medical devices.

  • How to notify the MHRA that you are going to undertake a clinical investigation of a medical device.

  • Details of the process changes for established medicines, effective from 1 March 2024, which apply specifically to chemical products.

  • An interpretation of the good manufacturing practice (GMP) requirements for specials manufacturers.

  • Information on the new regulations for the post-market surveillance of medical devices which come into effect on 16 June 2025.

  • How new recommendations could make healthcare AI safer, clearer and fairer for patients, professionals, providers and developers across the UK.

  • A step-by-step guide on using the MORE Platform for Registrations for Submissions of device related incidents.

  • The MHRA’s AI Airlock second phase ran between April 2025 and May 2026. This report does not constitute formal MHRA guidance.

  • UK guideline on GMP for decentralised manufacturing, ensuring compliance with EU GMP principles for safe, quality medicinal products.

  • Clinical trial applications that need expert advice from a specialist group or committee.

  • Anyone in Northern Ireland selling medicines to the public via a website must still comply with the requirement to apply the EU common logo.

  • The Early Access to Medicines Scheme (EAMS) aims to give patients with life threatening or seriously debilitating conditions early access to medicines that show early signs of having a major advantage over existing therapeut…

  • The MHRA accepts an Active Substance Master File and/or a Certificate of Suitability in both new national initial Marketing Authorisation Applications (MAA) and in Marketing Authorisation Variation (MAV) applications.

  • Provides a standard framework for NHS procurement professionals to assess non-financial value when buying medical technology.